Dpp-iv resistant gip hybrid polypeptides with selectable properties

A method to treat or prevent cardiovascular disease or condition in a patient in need thereof comprising, administering to the patient a therapeutically effective amount of a gastric inhibitory polypeptide (GIP) compound,

• wherein
• said GIP compound is a GIP analog, derivative or hybrid polypeptide exhibiting at least one hormonal activity, said polypeptide comprising a first bio-active peptide hormone module covalently linked to at least one additional bio-active peptide hormone module;
• the bio-active peptide hormone modules are independently selected from the group consisting of:
• component peptide hormones, fragments of component peptide hormones that exhibit at least one hormonal activity of the component peptide hormones, analogs and derivatives of component peptide hormones that exhibit at least one hormonal activity of the component peptide hormones, fragments of analogs and derivatives of component peptide hormones that exhibit at least one hormonal activity of the component peptide hormones, and peptidic enhancers;
• the component peptide hormone of the first bio-active peptide hormone module is a GIP modified for resistance to DPP-IV;
• the component peptide hormone of the at least one additional bio-active peptide hormone modules are independently selected from the group consisting of:
• amylin, adrenomedullin (ADM), calcitonin (CT), calcitonin gene related peptide (CGRP), intermedin, cholecystokinin (CCK), leptin, peptide YY (PYY), glucagon-like peptide-1 (GLP-I), glucagon-like peptide 2 (GLP-2), oxyntomodulin (OXM), a catestain, a natriuretic peptide, a urocortin family peptide, a neuromedin family peptide, exendin-3, and exendin-4;
• the peptidic enhancers are independently selected from the group consisting of:
• structural motifs of component peptide hormones that impart a desired chemical stability, conformational stability, metabolic stability, bioavailability, organ/tissue targeting, receptor interaction, protease inhibition, plasma protein binding, or other pharmacokinetic characteristic to the GIP compound polypeptide, and structural motifs of analogs or derivatives of component peptide hormones that impart a desired chemical stability, conformational stability, metabolic stability, bioavailability, organ/tissue targeting, receptor interaction, protease inhibition, plasma protein binding, or other pharmacokinetic characteristic to the GIP compound polypeptide;
• and
• at least one of the bio-active peptide hormone modules exhibits at least one hormonal activity of a component peptide hormone.